Full Press Release Details
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer.
IDYA
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Key Takeaway: IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer
Price reaction · baseline $43.58 (2024-03-11 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close · peak
+2.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma